ѻý

<ѻý class="page-title">Meeting Coverage

ASH: Hematology

<ѻý class="page-description">American Society of Hematology
<ѻý class="section_title">Latest ASH: Hematology Meeting Coverage
Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma

Will results revive ibrutinib role in MCL following withdrawal of accelerated approval?

December 13, 2023
'Half-Matched' BMTs Effective in Severe Sickle Cell Disease

High survival rates observed in patients not normally suitable for transplant

December 13, 2023
Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder

24 weeks of daily treatment significantly reduced recurrent nosebleeds in HHT trial

December 13, 2023
Four Drugs Top Three for Upfront Treatment of Multiple Myeloma

Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned

December 13, 2023
Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia

Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease

December 12, 2023
Novel Monoclonal Antibody Reduces Bleeds in Hemophilia A and B

Marstacimab reduced the annualized bleeding rate versus on-demand, prophylactic treatments

December 12, 2023
Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosis

Combos with navitoclax or pelabresib led to more patients achieving reductions

December 12, 2023
Axatilimab Shows Efficacy in Recurrent/Refractory GVHD

Highest overall response rate and least toxicity seen with lowest dose

December 11, 2023
MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia

No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD

December 11, 2023
ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission

Better 2-year PFS, OS, but not applicable to primary refractory disease

December 10, 2023
Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients

Time-limited approach based on MRD response outperforms FCR, but U.S. applicability unclear

December 10, 2023
Emicizumab Safe, Effective, in Infants With Hemophilia A

More than half of children in study had no treated bleeds at follow-up of more than 100 weeks

December 10, 2023
Lovo-Cel 'Life-Changing, Transformative' in Sickle Cell Disease

Near complete resolution of pain events in patients, including adolescents

December 10, 2023
Benefits of Myeloma Regimens in the Real World Fall Well Short of Trials

Survival 75% worse compared with outcomes seen in registrational studies

December 10, 2023
<ѻý class="section_title">Videos